| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-06-02 | Definigen (UK) | £2.3 million (€2.83 million) | series A financing round | Cambridge Enterprise (UK) 24 Haymarket (UK) Dr. Jonathan Milner (UK) Providence Investment Company (UK), Cambridge Capital Group (UK) LBA, Wren Capital (UK), Ranworth Capital (UK) | Series A financing round | |
| 2014-05-30 | BiolineRx (Israel) | up to $20 million | private placement | Lincoln Park Capital Fund (USA) | Cancer - Oncology - Infectious diseases - Digestive diseases - Inflammatory diseases - Dermatological diseases - Metabolic diseases | Private placement |
| 2014-05-29 | Epidarex Capital (UK) | £47.5 million (€58.3 million) | financing round | Eli Lilly (USA) King’s College London (UK) European Investment Fund (EU) Scottish Enterprise (UK) Strathclyde Pension Fund (UK), University of Edinburgh (UK) University of Glasgow (UK) University of Aberdeen (UK) | Financing round | |
| 2014-05-28 | Moberg Pharma (Sweden) | SEK 60 million (€6.64 million) | private placement of new shares | undisclosed Swedish and international institutional qualified investors | Private placement | |
| 2014-05-22 | Mucosis (The Netherlands) | up to €5 million | credit line | the Netherlands Enterprise Agency (The Netherlands) | Infectious diseases | Credit line |
| 2014-05-21 | Lysogene (France) | €16.5 million | series A financing round | Bpifrance (France) Novo Seeds (Denmark) Sofinnova Partners (France) | Rare diseases | Series A financing round |
| 2014-05-21 | Lanthio Pharma (The Netherlands) | up to €3.6 million | loan | Dutch Government agency RVO (The Netherlands) | Lung diseases | Loan |
| 2014-05-13 | Pledpharma (Sweden) | SEK 20,25 million (€2.2 million) | private placement | Cancer - Oncology | Private placement | |
| 2014-05-08 | Lophius Biosciences (Germany) | €2 million | VRD (Germany) - S-Refit (Germany) | Diagnostic - Infectious diseases - Immunological diseases - Neurodegenerative diseases | Establishment of a new subsidiary in the EU | |
| 2014-05-08 | Imaginab (USA - CA) | $21 Million | series B financing round | Mérieux Développement (France) Novartis Venture Funds (Switzerland) Cycad Group (USA) Nextech Invest | Cancer - Oncology - Autoimmune diseases | Series B financing round |
| 2014-05-06 | Avillion (UK) | undisclosed | fundraising | Royalty Pharma (UK) | Fundraising | |
| 2014-05-05 | Lundbeck (Denmark) | grant | The Michael J. Fox Foundation - MJFF (USA) | Neurodegenerative diseases | Grant | |
| 2014-05-05 | Anokion (Switzerland) | CHF 33 million (€27.1 million) | series A financing round | Novartis Venture Fund (Switzerland) Novo Ventures (Denmark) Versant Ventures (USA) | Allergic diseases - Autoimmune diseases - Immunological diseases | Series A financing round |
| 2014-04-30 | Oxford BioMedica (UK) | £2.2 million (€2.68 million) | grant | BioMedical Catalyst Fund (UK) | Neurodegenerative diseases | Grant |
| 2014-04-30 | Celenys (France) | €1 million | financing round | Go Capital (France) NCI (France) | Financing round | |
| 2014-04-29 | Atlas Genetics (UK) | £16.9 million (€20.59 million) | series B financing round | Novartis Venture Funds (Switzerland), Consort Medical (UK), LSP - Life Sciences Partners (The Netherlands), BB Biotech Ventures (Switzerland), Johnson & Johnson Development Corporation (USA), YFM Equity Partners (UK) and private investors | Diagnostic - Infectious diseases | Series B financing round |
| 2014-04-29 | Skyepharma (UK) | capital increase | Capital increase | |||
| 2014-04-29 | Silence Therapeutics (UK) | £11.4 million | private placement | new and existing institutional investors, and certain participating directors | Private placement | |
| 2014-04-28 | Enterome Bioscience (France) | €10 million | series B financing round | Seventure Partners (France), Lundbeckfond Ventures, Omnes Capital (France) | Digestive diseases - Inflammatory diseases - Metabolic diseases | Series B financing round |
| 2014-04-28 | SYMPATH consortium (AFFiRiS AG (Austria), Biolution GmbH (Austria), University Hospital Bordeaux (France), INSERM F-CRIN Toulouse (France), Prosenex Ambulatorium Betriebs-GmbH (Austria), Medical University Innsbruck, Department of Neurology (Austria), Forschungszentrum Jülich GmbH (Germany),University Hospital Toulouse (France) ) | € 6 million | grant | European Commission’s Seventh Framework Program (FP7) | Neurodegenerative diseases | Grant |
